{"protocolSection":{"identificationModule":{"nctId":"NCT00402051","orgStudyIdInfo":{"id":"11077"},"secondaryIdInfos":[{"id":"H3E-SB-S109","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC"},"statusModule":{"statusVerifiedDate":"2010-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-11"},"primaryCompletionDateStruct":{"date":"2008-12","type":"ACTUAL"},"completionDateStruct":{"date":"2009-05","type":"ACTUAL"},"studyFirstSubmitDate":"2006-11-17","studyFirstSubmitQcDate":"2006-11-17","studyFirstPostDateStruct":{"date":"2006-11-22","type":"ESTIMATED"},"resultsFirstSubmitDate":"2009-11-30","resultsFirstSubmitQcDate":"2009-11-30","resultsFirstPostDateStruct":{"date":"2010-01-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-02-01","lastUpdatePostDateStruct":{"date":"2010-02-17","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This is a two-arm, parallel, open-label, Phase 2 multicenter study of pemetrexed as first line combination therapy with either cisplatin or carboplatin in the palliative setting of stage IIIb and IV non-small cell lung cancer patients. Approximately 130 patients will be included in about 15 centers in Germany and randomized to one of the above treatment regimens in a 1:1 ratio. Chemotherapy will be administered over a maximum of six cycles with a standard length of 21 days. Primary objective will be the Progression Free Survival Time of patients as assessed in both treatment arms."},"conditionsModule":{"conditions":["Non-Small-Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":133,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin"]},{"label":"Pemetrexed + Carboplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"500 mg/m2, intravenous (IV), every 21 days x 6 cycles","armGroupLabels":["Pemetrexed + Carboplatin","Pemetrexed + Cisplatin"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m2, intravenous (IV), every 21 days x 6 cycles","armGroupLabels":["Pemetrexed + Cisplatin"]},{"type":"DRUG","name":"Carboplatin","description":"Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles","armGroupLabels":["Pemetrexed + Carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)","description":"For this study, we used the exponential distribution (assumption done for the calculation of the sample size) to estimate the PFS rate. The PFS rate (%) and the 95% confidence intervals were calculated based on the following formula: exp(-6 λ) ± 1.96 \\* exp(-6 λ) \\* (-6 λ)/√r. Where λ was calculated based on the Maximum-Likelihood estimator for ln(λ) as given by (Collett 2003): ln(λ) = ln\\[ r / ∑ti \\] with r = number of patients with events up to 6 months, ti = survival time of patient i (i=1,…,n), event or censored up to 6 months, and n= total number of patients per treatment group.","timeFrame":"Randomization to Month 6"}],"secondaryOutcomes":[{"measure":"Overall Survival","description":"Defined as the time from randomization to the date of death from any cause.","timeFrame":"Randomization to date of death from any cause (up to 1 year)"},{"measure":"Number of Participants With Tumor Response (as Basis for Response Rate)","description":"Best overall response was evaluated using RECIST Criteria which define when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatment. CR: complete response, disappearance of all target lesions; PR: partial response, 30% decrease in sum of the longest diameter of target lesions; PD: progressive disease, 20% increase in sum of the longest diameter of target lesions; SD: stable disease, small changes not meeting above criteria. Response Rate: number of participants with response(CR+PR)per total population, multiplied by 100 to give a percentage.","timeFrame":"Every 6 weeks for 6 months during the treatment period, and every 3 months during the follow-up period, until disease progression"},{"measure":"Time to Treatment Failure (TTF)","description":"Defined as time from randomization to the first date of disease progression, death due to any cause, or early discontinuation of treatment (any reason), whichever occurred first","timeFrame":"Randomization to stopping of treatment, progression, death or initiation of further chemotherapy, whichever occurs first (up to 1 year)"},{"measure":"Pharmacology Toxicities","description":"Number of patients experiencing Grade 3 or 4 hematologic and non-hematologic adverse events (AEs) possibly related to study drug or protocol procedures in this study (a subset of those listed in the AE Module). AEs were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). Grade 3 AEs are severe and undesirable; Grade 4 AEs are life-threatening or disabling.","timeFrame":"Every 21-day cycle for up to 6 cycles"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cytologically and/or histologically confirmed NSCLC Stage IIIb or IV\n* No previous systemic chemotherapy for this cancer\n* At least one uni-dimensionally measurable lesion meeting Response Evaluation Criteria In Solid Tumors (RECIST) criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 and adequate organ function\n* Prior radiation therapy allowed but limited to \\<25% of the patient's bone marrow\n\nExclusion Criteria:\n\n* Serious concomitant systemic disorder or active infection\n* Mild to moderate renal insufficiency, but unable to interrupt salicylates or other nonsteroidal anti-inflammatory drugs\n* Symptomatic central nervous system (CNS) metastases requiring concurrent corticosteroid therapy\n* Presence of clinically significant third-space fluid collections","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLilly (1-877-285-4559) or 1-317-615-4559 Mon -Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Coswig","zip":"D-01640","country":"Germany","geoPoint":{"lat":51.13204,"lon":13.58312}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frankfurt","zip":"65929","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Großhansdorf","zip":"D-22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Halle","zip":"D-06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hamburg","zip":"D-21075","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Hofheim","zip":"D-65719","country":"Germany","geoPoint":{"lat":49.65749,"lon":8.41385}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Homburg/Saar","zip":"66421","country":"Germany"},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Immenhausen","zip":"D-34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Leipzig","zip":"04207","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lübeck","zip":"23538","country":"Germany","geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mainz","zip":"55131","country":"Germany","geoPoint":{"lat":49.98185,"lon":8.28008}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"München","zip":"81664","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}}]},"referencesModule":{"references":[{"pmid":"23332288","type":"DERIVED","citation":"Schuette WH, Groschel A, Sebastian M, Andreas S, Muller T, Schneller F, Guetz S, Eschbach C, Bohnet S, Leschinger MI, Reck M. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer. 2013 May;14(3):215-23. doi: 10.1016/j.cllc.2012.10.001. Epub 2013 Jan 16."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"136 patients signed informed consent. Of these, 3 patients were discontinued prior to randomization (1x protocol entry criteria not met, 2x patient decision); 133 patients were randomized, 130 patients started study drug.","groups":[{"id":"FG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"FG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"66"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"65"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Completed 6 treatment cycles and 30 days of follow-up after last dose of study drug","numSubjects":"28"},{"groupId":"FG001","comment":"Completed 6 treatment cycles and 30 days of follow-up after last dose of study drug","numSubjects":"32"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"38"},{"groupId":"FG001","numSubjects":"35"}]}],"dropWithdraws":[{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death - Related to Study Drug","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Death Due to Study Disease","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Death Due to Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"BG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"130"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.3","spread":"8.43"},{"groupId":"BG001","value":"62.4","spread":"7.51"},{"groupId":"BG002","value":"62.4","spread":"7.95"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"42"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"88"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"130"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"65"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"130"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Classifies patients according to their functional impairment. Scores range from 0 (Fully Active) to 5 (Death).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0 - Fully Active","categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"85"}]}]},{"title":"1 - Ambulatory, Restricted Strenuous Activity","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"45"}]}]}]},{"title":"Histopathology","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Squamous Cell Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"25"}]}]},{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"82"}]}]},{"title":"Large Cell Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"9"}]}]},{"title":"Mixed Cell Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Bronchioalveolar Carcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"NSCLC, Not Otherwise Specified","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}]}]}]},{"title":"Presence of Bone and Brain Metastases","description":"Presents specifically participants with bone and brain metastases","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Bone Metastases","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]}]},{"title":"Brain Metastases","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Smoking Status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never Smoked","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]}]},{"title":"Past Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"83"}]}]},{"title":"Current Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"31"}]}]}]},{"title":"Stage of disease","description":"For all patients randomized, N=66 for Pemetrexed + Cisplatin, N=67 for Pemetrexed + Carboplatin","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Stage IIIb (locally advanced disease)","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"14"}]}]},{"title":"Stage IV (metastatic disease)","categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"119"}]}]}]},{"title":"Time Since Patient Stopped Smoking","description":"For past smokers only: N=41 for Pemetrexed + Cisplatin, N=42 for Pemetrexed + Carboplatin","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10.1","spread":"12.31"},{"groupId":"BG001","value":"7.4","spread":"10.56"},{"groupId":"BG002","value":"8.7","spread":"11.46"}]}]}]},{"title":"Use of Tobacco Products","description":"For past and current smokers only: N=56 for Pemetrexed +\n\nCisplatin, N=58 for Pemetrexed + Carboplatin:","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.7","spread":"12.74"},{"groupId":"BG001","value":"34.6","spread":"11.47"},{"groupId":"BG002","value":"33.2","spread":"12.15"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)","description":"For this study, we used the exponential distribution (assumption done for the calculation of the sample size) to estimate the PFS rate. The PFS rate (%) and the 95% confidence intervals were calculated based on the following formula: exp(-6 λ) ± 1.96 \\* exp(-6 λ) \\* (-6 λ)/√r. Where λ was calculated based on the Maximum-Likelihood estimator for ln(λ) as given by (Collett 2003): ln(λ) = ln\\[ r / ∑ti \\] with r = number of patients with events up to 6 months, ti = survival time of patient i (i=1,…,n), event or censored up to 6 months, and n= total number of patients per treatment group.","populationDescription":"Full Analysis Set: All patients randomized who received at least one dose of study drug","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage","timeFrame":"Randomization to Month 6","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8","lowerLimit":"40.3","upperLimit":"65.3"},{"groupId":"OG001","value":"39.3","lowerLimit":"27.8","upperLimit":"50.8"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Hypothesis testing was done independently for each treatment arm (no direct treatment group comparison).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"6-Month PFS Rate","paramValue":"52.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"40.3","ciUpperLimit":"65.3"},{"groupIds":["OG001"],"groupDescription":"Hypothesis testing was done independently for each treatment arm (no direct treatment group comparison).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"6-Month PFS Rate","paramValue":"39.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"27.8","ciUpperLimit":"50.8"}]},{"type":"SECONDARY","title":"Overall Survival","description":"Defined as the time from randomization to the date of death from any cause.","populationDescription":"Full Analysis Set: All patients randomized who received at least one dose of study drug","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to date of death from any cause (up to 1 year)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","lowerLimit":"9.2","upperLimit":"14.9"},{"groupId":"OG001","value":"8.9","lowerLimit":"6.0","upperLimit":"12.2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Tumor Response (as Basis for Response Rate)","description":"Best overall response was evaluated using RECIST Criteria which define when cancer patients improve (\"respond\"), stay the same (\"stabilize\"), or worsen (\"progression\") during treatment. CR: complete response, disappearance of all target lesions; PR: partial response, 30% decrease in sum of the longest diameter of target lesions; PD: progressive disease, 20% increase in sum of the longest diameter of target lesions; SD: stable disease, small changes not meeting above criteria. Response Rate: number of participants with response(CR+PR)per total population, multiplied by 100 to give a percentage.","populationDescription":"Full Analysis Set: All patients randomized who received at least one dose of study drug","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Every 6 weeks for 6 months during the treatment period, and every 3 months during the follow-up period, until disease progression","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"13"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}]}]},{"title":"Disease Progression","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"15"}]}]},{"title":"Unknown/Not Done","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]}],"analyses":[{"groupIds":["OG000"],"groupDescription":"Response rates were evaluated separately for each treatment arm","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Best Overall Response Rate (%)","paramValue":"32.3","ciPctValue":"95","ciLowerLimit":"21.2","ciUpperLimit":"45.1"},{"groupIds":["OG001"],"groupDescription":"Response rates were evaluated separately for each treatment arm","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Best Overall Response Rate (%)","paramValue":"20.0","ciPctValue":"95","ciLowerLimit":"11.1","ciUpperLimit":"31.8"}]},{"type":"SECONDARY","title":"Time to Treatment Failure (TTF)","description":"Defined as time from randomization to the first date of disease progression, death due to any cause, or early discontinuation of treatment (any reason), whichever occurred first","populationDescription":"Full Analysis Set: All patients randomized who received at least one dose of study drug","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to stopping of treatment, progression, death or initiation of further chemotherapy, whichever occurs first (up to 1 year)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","lowerLimit":"2.3","upperLimit":"4.6"},{"groupId":"OG001","value":"3.4","lowerLimit":"2.3","upperLimit":"4.8"}]}]}]},{"type":"SECONDARY","title":"Pharmacology Toxicities","description":"Number of patients experiencing Grade 3 or 4 hematologic and non-hematologic adverse events (AEs) possibly related to study drug or protocol procedures in this study (a subset of those listed in the AE Module). AEs were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). Grade 3 AEs are severe and undesirable; Grade 4 AEs are life-threatening or disabling.","populationDescription":"Full Analysis Set: All patients randomized who received at least one dose of study drug","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Every 21-day cycle for up to 6 cycles","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles"},{"id":"OG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"65"}]}],"classes":[{"title":"Any Grade 3/4 Toxicity","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"36"}]}]},{"title":"Grade 3/4 Leucopenia","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"}]}]},{"title":"Grade 3/4 Neutropenia","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"}]}]},{"title":"Grade 3/4 Anemia","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]},{"title":"Grade 3/4 Thrombocytopenia","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]},{"title":"Grade 3/4 Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}]},{"title":"Grade 3/4 Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Grade 3/4 Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3/4 Anorexia","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Grade 3/4 Urinary Tract Infection","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Cisplatin 75 mg/m2 IV, every 21 days for 6 cycles","seriousNumAffected":22,"seriousNumAtRisk":65,"otherNumAffected":61,"otherNumAtRisk":65},{"id":"EG001","title":"Pemetrexed + Carboplatin","description":"Pemetrexed 500 mg/m2 intravenous (IV); Carboplatin area under the concentration curve (AUC) 5 IV, every 21 days for 6 cycles","seriousNumAffected":28,"seriousNumAtRisk":65,"otherNumAffected":59,"otherNumAtRisk":65}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Anaemia of malignant disease","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":65}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Cardiovascular disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Tachyarrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Cerebral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":65}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Osteolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Grand mal convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Anxiety disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Mental disorder due to a general medical condition","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Hip arthroplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":65}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Haemorrhage","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":65},{"groupId":"EG001","numEvents":27,"numAffected":19,"numAtRisk":65}]},{"term":"Haemoglobinaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":65}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":17,"numAtRisk":65},{"groupId":"EG001","numEvents":41,"numAffected":24,"numAtRisk":65}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":18,"numAtRisk":65},{"groupId":"EG001","numEvents":62,"numAffected":25,"numAtRisk":65}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":9,"numAtRisk":65},{"groupId":"EG001","numEvents":39,"numAffected":18,"numAtRisk":65}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":17,"numAtRisk":65},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":65}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":65},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":65}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":42,"numAtRisk":65},{"groupId":"EG001","numEvents":46,"numAffected":27,"numAtRisk":65}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":24,"numAtRisk":65},{"groupId":"EG001","numEvents":10,"numAffected":8,"numAtRisk":65}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":25,"numAtRisk":65},{"groupId":"EG001","numEvents":31,"numAffected":24,"numAtRisk":65}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":9,"numAffected":5,"numAtRisk":65}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":65}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":65}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":65}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":65}]},{"term":"Anorexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":16,"numAtRisk":65},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":65}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":65}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":65}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":3,"numAtRisk":65}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":65},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":65}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":65}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":65}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":13,"numAtRisk":65},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":65}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":65}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":65}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":65}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":65},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":65}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 9.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"1-800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}